Rasmussen Christina B, Kjaer Susanne K, Albieri Vanna, Bandera Elisa V, Doherty Jennifer A, Høgdall Estrid, Webb Penelope M, Jordan Susan J, Rossing Mary Anne, Wicklund Kristine G, Goodman Marc T, Modugno Francesmary, Moysich Kirsten B, Ness Roberta B, Edwards Robert P, Schildkraut Joellen M, Berchuck Andrew, Olson Sara H, Kiemeney Lambertus A, Massuger Leon F A G, Narod Steven A, Phelan Catherine M, Anton-Culver Hoda, Ziogas Argyrios, Wu Anna H, Pearce Celeste L, Risch Harvey A, Jensen Allan
Am J Epidemiol. 2017 Jan 1;185(1):8-20. doi: 10.1093/aje/kww161. Epub 2016 Dec 9.
Inflammation has been implicated in ovarian carcinogenesis. However, studies investigating the association between pelvic inflammatory disease (PID) and ovarian cancer risk are few and inconsistent. We investigated the association between PID and the risk of epithelial ovarian cancer according to tumor behavior and histotype. We pooled data from 13 case-control studies, conducted between 1989 and 2009, from the Ovarian Cancer Association Consortium (OCAC), including 9,162 women with ovarian cancers, 2,354 women with borderline tumors, and 14,736 control participants. Study-specific odds ratios were estimated and subsequently combined into a pooled odds ratio using a random-effects model. A history of PID was associated with an increased risk of borderline tumors (pooled odds ratio (pOR) = 1.32, 95% confidence interval (CI): 1.10, 1.58). Women with at least 2 episodes of PID had a 2-fold increased risk of borderline tumors (pOR = 2.14, 95% CI: 1.08, 4.24). No association was observed between PID and ovarian cancer risk overall (pOR = 0.99, 95% CI: 0.83, 1.19); however, a statistically nonsignificantly increased risk of low-grade serous tumors (pOR = 1.48, 95% CI: 0.92, 2.38) was noted. In conclusion, PID was associated with an increased risk of borderline ovarian tumors, particularly among women who had had multiple episodes of PID. Although our results indicated a histotype-specific association with PID, the association of PID with ovarian cancer risk is still somewhat uncertain and requires further investigation.
炎症与卵巢癌发生有关。然而,调查盆腔炎性疾病(PID)与卵巢癌风险之间关联的研究较少且结果不一致。我们根据肿瘤行为和组织类型调查了PID与上皮性卵巢癌风险之间的关联。我们汇总了1989年至2009年间卵巢癌协会联盟(OCAC)开展的13项病例对照研究的数据,其中包括9162例卵巢癌女性、2354例交界性肿瘤女性和14736例对照参与者。估计了各研究的比值比,随后使用随机效应模型将其合并为汇总比值比。PID病史与交界性肿瘤风险增加有关(汇总比值比(pOR)=1.32,95%置信区间(CI):1.10,1.58)。至少有2次PID发作的女性患交界性肿瘤的风险增加了2倍(pOR=2.14,95%CI:1.08,4.24)。总体上未观察到PID与卵巢癌风险之间存在关联(pOR=0.99,95%CI:0.83,1.19);然而,注意到低级别浆液性肿瘤的风险有统计学上无显著意义的增加(pOR=1.48,95%CI:0.92,2.38)。总之,PID与卵巢交界性肿瘤风险增加有关,尤其是在有多次PID发作的女性中。虽然我们的结果表明与PID存在组织类型特异性关联,但PID与卵巢癌风险的关联仍有些不确定,需要进一步研究。